IPCALAB2019-04-012019-06-30in-bse-fin:OneOperatingExpenses01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares IPCALAB 2019-04-01 2020-03-31 2019-07-22 INR Crores First quarter Single segment Pharmaceuticals 2019-04-01 2019-06-30 Unaudited Standalone 10110100000.00 194300000.00 10304400000.00 3216400000.00 459100000.00 -49800000.00 2055000000.00 44700000.00 420400000.00 2479000000.00 8624800000.00 1679600000.00 0.00 1679600000.00 365000000.00 -5900000.00 359100000.00 0.00 1320500000.00 0.00 0.00 0.00 0.00 1320500000.00 -8600000.00 1311900000.00 0.00 0.00 252700000.00 2 10.45 10.45 0.00 0.00 10.45 10.45 0.00 0.00 0.00 Notes: n1 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 13, n2019. The Statutory Auditors have carried out the limited review of the results. n2 Effective April 1, 2019, the Company adopted Ind AS 116 Leases and applied to all contracts having lease components existing on April 1, 2019 using the modified retrospective approach and accordingly, recognized Right of Use assets and Lease liability without carrying out retrospective adjustments. The effect of this adoption is not material on the results for the period. n3 The Company has only one operating segment viz. 'Pharmaceuticals'. n4 Figures of the previous periods have been regrouped wherever necessary. The figures for the quarter ended March 31, 2019 are the balancing figures between audited figures in respect of the full financial year 2018-19 and the published year to date unaudited figures upto December 31,2018 . n other expenses 2479000000.00